These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37421190)

  • 1. Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter, nationwide study (SIPPRA-B Study).
    Oliveira Pinheiro F; Seabra Rato M; Madureira P; Araújo F; Salvador MJ; Fraga V; Brites L; Cunha Santos F; Silva A; Lopes AR; Cruz M; Vilas Boas JP; Pontes Ferreira M; Samões B; Beirão T; Santos I; Carvalho D; Costa L; Bernardes M
    ARP Rheumatol; 2023; 2(2):111-119. PubMed ID: 37421190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
    Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
    Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia.
    Sharma C; Keen H
    Intern Med J; 2019 Apr; 49(4):519-525. PubMed ID: 30230146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
    Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
    Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
    Ranza R; de la Vega MC; Laurindo IMM; Gómez MG; Titton DC; Kakehasi AM; Brigante A; Benitez A; Ranzolin A; Granel A; Cappuccio AM; Quinteros A; Hayata ALS; Smichowski A; Duarte ÂLBP; Kahlow BS; Andia CS; Brenol CV; Velozo E; Mussano E; Soriano ER; Christopoulos GB; da Rocha Castelar Pinheiro G; de Castro GRW; Casado G; da Silveira Carvalho HM; Exeni IE; da Silveira IG; Petkovic I; Pereira IA; da Costa IP; Rosa JE; Miranda JRS; de Moraes JCB; Bertolo MB; Buhl M; Lázaro MA; da Sauma MFLC; de Medeiros Pinheiro M; Díaz M; de Vechi MVSS; Cerda OL; Astesana P; Curi PF; Louzada-Jr P; Teodoro RB; Toledo RA; Papasidero S; Valim V; Fernandes V; Saurit V; Bianchi WA; ; de Melo Costa Pinto R; Descalzo MA; Gomez-Reino JJ
    Clin Rheumatol; 2019 Aug; 38(8):2129-2139. PubMed ID: 31016578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
    Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
    Novella-Navarro M; Plasencia C; Tornero C; Navarro-Compán V; Cabrera-Alarcón JL; Peiteado-López D; Nuño L; Monjo-Henry I; Franco-Gómez K; Villalba A; Balsa A
    Arthritis Res Ther; 2020 Dec; 22(1):284. PubMed ID: 33298140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
    Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
    Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
    Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
    Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
    Jung JY; Lee E; Kim JW; Suh CH; Kim HA
    Clin Exp Rheumatol; 2023 May; 41(5):1034-1041. PubMed ID: 36062753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.